Longitudinal Magnetic Resonance Imaging Detects Onset and Progression of Chronic Rhinosinusitis from Infancy to School Age in Cystic Fibrosis
Lena Wucherpfennig, Felix Wuennemann, Monika Eichinger, Niclas Schmitt, Angelika Seitz, Ingo Baumann, Mirjam Stahl, Simon Y. Graeber, Jaehi Chung, Jens‐Peter Schenk, Abdulsattar Alrajab, Hans‐Ulrich Kauczor, Marcus Mall, Olaf Sommerburg, Mark O. Wielpütz
Abstract
Abstract Rationale Chronic rhinosinusitis (CRS) contributes to morbidity in patients with cystic fibrosis (CF). However, longitudinal data on CRS onset and progression is lacking. Objectives To longitudinally evaluate CRS in CF from infancy to school age with paranasal sinus magnetic resonance imaging (MRI). Methods A total of 64 children with CF (mean age at baseline, 1.1 ± 1.6 yr; range, 0–5 yr) underwent a mean of 5.8 ± 2.2 (range, 3–11 yr) subsequent annual MRI examinations. Additional 24 children (9.2 ± 4.4 yr; range, 3–17 yr) homozygous for the F508del mutation underwent MRI before and at least 2 months after starting lumacaftor/ivacaftor. MRI was assessed using the previously evaluated CRS-MRI score. Results In infancy, 65–87% of paranasal sinuses were opacified, and mucosal swelling was the dominant abnormality (58–97%). At preschool age (1–5 yr), 79–94% of sinuses were opacified (P < 0.05 vs. infancy), and mucosal swelling was the most dominant abnormality (79–94%; P < 0.05). At school age (at least 6 yr), almost all sinuses were opacified (71–99%; P < 0.001–0.357 vs. preschool age), and mucopyoceles were the dominant abnormality in maxillary and frontal sinuses (53–56%; P < 0.05–0.808). The CRS-MRI sum score increased from 22.4 ± 9.6 in infancy to 34.2 ± 9.6 in preschool age (P < 0.001) and was 34.0 ± 5.7 in school age (P = 0.052). In children under lumacaftor/ivacaftor therapy, the CRS-MRI sum score (−0.5 ± 3.3; P < 0.05) and maxillary sinus subscore (−0.5 ± 1.5; P < 0.05) improved. Conclusions Longitudinal paranasal sinus MRI detects an early onset and progression of the severity of CRS from infancy to school age, and response to lumacaftor/ivacaftor therapy in children with CF. Our data support its role in the comprehensive noninvasive monitoring of CRS in children with CF. Clinical trial registered with www.clinicaltrials.gov (NCT 02270476).